AU5687199A - Use of anti-angiogenic agents for inhibiting vessel wall injury - Google Patents

Use of anti-angiogenic agents for inhibiting vessel wall injury

Info

Publication number
AU5687199A
AU5687199A AU56871/99A AU5687199A AU5687199A AU 5687199 A AU5687199 A AU 5687199A AU 56871/99 A AU56871/99 A AU 56871/99A AU 5687199 A AU5687199 A AU 5687199A AU 5687199 A AU5687199 A AU 5687199A
Authority
AU
Australia
Prior art keywords
vessel wall
angiogenic agents
wall injury
inhibiting vessel
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56871/99A
Inventor
Charles L Brown
Steve Gorlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Vascular Concepts Inc
Original Assignee
Global Vascular Concepts Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Vascular Concepts Inc filed Critical Global Vascular Concepts Inc
Publication of AU5687199A publication Critical patent/AU5687199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
AU56871/99A 1998-08-24 1999-08-24 Use of anti-angiogenic agents for inhibiting vessel wall injury Abandoned AU5687199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9757998P 1998-08-24 1998-08-24
US60097579 1998-08-24
PCT/US1999/019218 WO2000010552A2 (en) 1998-08-24 1999-08-24 Use of anti-angiogenic agents for inhibiting vessel wall injury

Publications (1)

Publication Number Publication Date
AU5687199A true AU5687199A (en) 2000-03-14

Family

ID=22264134

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56871/99A Abandoned AU5687199A (en) 1998-08-24 1999-08-24 Use of anti-angiogenic agents for inhibiting vessel wall injury

Country Status (2)

Country Link
AU (1) AU5687199A (en)
WO (1) WO2000010552A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
ES2316194T3 (en) * 1998-10-28 2009-04-01 Cornell Research Foundation, Inc. METHODS FOR THE REGULATION OF ANGIOGENESIS AND VASCULAR INTEGRITY USING THE BDNF, NT-3 AND NT-4 LIGANDS.
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
EP1214077B1 (en) * 1999-09-21 2004-01-28 Institut de Cardiologie de Montreal Local delivery of 17-beta estradiol for improving vascular endothelium function after vascular injury
EP1227804B1 (en) * 1999-11-09 2007-08-22 Pharmacia Corporation Use of eplerenone for treating restenosis
DE19957342A1 (en) * 1999-11-29 2001-05-31 Gruenenthal Gmbh Treatment of interleukin (IL)-12 mediated illnesses comprises simultaneous administration of thalidomide or analogue and antiinflammatory cytokine
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
CA2416152A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US6436629B1 (en) * 2000-10-27 2002-08-20 The Regents Of The University Of California Modulating angiogenesis
JP2004537499A (en) * 2000-11-27 2004-12-16 エントレメッド インコーポレイテッド Anti-angiogenic drugs
AU2002243552C1 (en) * 2001-01-12 2006-08-31 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
DE10115740A1 (en) 2001-03-26 2002-10-02 Ulrich Speck Preparation for restenosis prophylaxis
US6625486B2 (en) 2001-04-11 2003-09-23 Advanced Cardiovascular Systems, Inc. Method and apparatus for intracellular delivery of an agent
AU4239302A (en) * 2001-06-28 2003-01-02 Pfizer Products Inc. Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
KR20040078683A (en) * 2002-01-30 2004-09-10 파마시아 코포레이션 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
EP1500401A4 (en) * 2002-04-22 2009-12-23 Res Found Itsuu Lab Drugs for treating vascular diseases
WO2004024206A1 (en) * 2002-09-12 2004-03-25 Estrogen Vascular Technology, Llc Apparatus and method for delivering compounds to a living organism
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medical device for drug delivery
WO2005007211A2 (en) * 2003-07-03 2005-01-27 Medtronic Vascular Inc. Medical devices with proteasome inhibitors for the treatment of restenosis
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
CA2558014A1 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
CA2580847C (en) 2004-09-20 2013-11-26 Research Development Foundation Coated stents
CA2588453A1 (en) * 2004-12-02 2006-06-08 Abbott Laboratories Use of a compound that activates a vitamin d receptor for reducing intimal hyperplasia, smooth muscle cell proliferation and restenosis in mammals
US7286295B1 (en) 2005-11-30 2007-10-23 Sandia Corporation Microoptical compound lens
US8399440B2 (en) 2006-03-20 2013-03-19 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
EP2356998A1 (en) * 2010-02-17 2011-08-17 Université de Liège A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) - placental lactogen (PL)-family protein
WO2011119536A1 (en) 2010-03-22 2011-09-29 Abbott Cardiovascular Systems Inc. Stent delivery system having a fibrous matrix covering with improved stent retention
CN113332298A (en) * 2021-05-27 2021-09-03 成都医学院 New use of minocycline as a tyrosine kinase inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096892A (en) * 1988-05-27 1992-03-17 The Children's Medical Center Corporation Arylsulfatase inhibition and potentiation of angiostatic steroids and heparin
CA2081205C (en) * 1990-06-11 2001-02-27 John W. Wilks Steroids which inhibit angiogenesis
EP0533816B1 (en) * 1990-06-15 1995-06-14 Cortrak Medical, Inc. Drug delivery apparatus
US5498238A (en) * 1990-06-15 1996-03-12 Cortrak Medical, Inc. Simultaneous angioplasty and phoretic drug delivery
AU1579092A (en) * 1991-02-27 1992-10-06 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
US5821234A (en) * 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
DK1159974T3 (en) * 1993-07-19 2007-11-26 Angiotech Pharm Inc Antiangiogenic compositions containing taxol and a non-biodegradable carrier and their use
US6025334A (en) * 1994-04-28 2000-02-15 Les Laboratoires Aeterna Inc. Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
US5788979A (en) * 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
AU5959398A (en) * 1997-01-09 1998-08-03 Localmed, Inc. Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels
CA2302017C (en) * 1997-08-25 2007-01-30 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Also Published As

Publication number Publication date
WO2000010552A2 (en) 2000-03-02
WO2000010552A3 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
AU5687199A (en) Use of anti-angiogenic agents for inhibiting vessel wall injury
GB9800795D0 (en) Prevention of multiple use of limited use devices
AU4908699A (en) Use of pit emulsions
HUP0102901A3 (en) Use of n-formyl hydroxylamines as antibacterial agents
GB2339905A8 (en) Use of mass-spectromy for detection mutations
TW349560U (en) Improvement for material of partitioned wall
PL346170A1 (en) Short oligonucleotides for the inhibition of vegf expression
HK1034778A1 (en) Process for the continuous liquid processing of photosensitive compositions having reduced levels ofresidues
AU141671S (en) Set of containers
ZA99134B (en) Measurement of container wall thickness.
PL353088A1 (en) Use of lubricants containing polyhydroxy compounds
AU2001253165A1 (en) Use of fluorocarbons for the prevention of surgical adhesions
IL148640A0 (en) Processes for the preparation of sumatriptan and related compounds
EP1117835A4 (en) Prevention of adhesions
HUP0102506A3 (en) The use of benzothiophene derivatives for increasing the level of acetylcholine
EP0984315A4 (en) Liquid crystal-aligning agent
GB9810127D0 (en) Prevention of surgical adhesions
GB2333953B (en) Bathtub tray
EP1038021A4 (en) Compounds and methods for the inhibition of protein-protein interactions
GB0019350D0 (en) Protection of vessels
AU3301400A (en) Monosulphates of 4 or 6 disaccharides
GB9812174D0 (en) Prevention of marine fouling
GB0015035D0 (en) Prevention of adhesions
GB9810855D0 (en) Use of compounds
GB9815514D0 (en) Use of PIT emulsions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase